Cited by 140Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

The DOI matches its Crossref record; 74 of the 76 references it cites were found in a registry or an index.

C‐reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin‐sensitizing treatment with thiazolidinediones

Nesto, R.·2004·Diabetic Medicine

DOI 10.1111/j.1464-5491.2004.01296.x

Open this paper in CoChat — free account

Abstract

Increased concentrations of the marker of inflammation, C‐reactive protein (CRP), are associated with insulin resistance, Type 2 diabetes and the development of cardiovascular disease. In particular, inflammation is closely associated with endothelial dysfunction and is recognized as one of the cardiovascular risk factors clustering in the Insulin Resistance Syndrome or Metabolic Syndrome. The exact mechanisms linking insulin resistance and inflammation remain unclear. However, the close association between insulin resistance and inflammation in atherogenesis suggests that therapies that address both parameters may have benefits in reducing diabetes‐related macrovascular complications. The thiazolidinedione class of oral anti‐diabetic agents are powerful insulin sensitizers that also have anti‐inflammatory properties. Treatment with these agents has a range of anti‐atherogenic effects, including reduced levels of CRP, plasminogen activator inhibitor‐1 (PAI‐1), TNF‐α and reactive oxygen species. Additionally, the insulin‐sensitizing effect of thiazolidinediones improves other factors of the Insulin Resistance Syndrome, including dyslipidaemia and hypertension. Outcome studies are underway to determine if the effects of improving insulin sensitivity and reducing inflammation will translate into clinical benefits and reduce the cardiovascular morbidity and mortality associated with insulin resistance and Type 2 diabetes.

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2004.01296.x

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
C-Reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction: A Potential Role for Cytokines Originating From Adipose Tissue?
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome
Festa, A., D’Agostino, R., Howard, G., Mykkänen, L., Tracy, R. P., & Haffner, S. M. (2000) · Circulation · doi:10.1161/01.cir.102.1.42 · Cited by 2,366
C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women
Ridker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · Circulation · doi:10.1161/01.cir.0000055014.62083.05 · Cited by 2,292
High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease
Ridker, P. M. (2001) · Circulation · doi:10.1161/01.cir.103.13.1813 · Cited by 1,402
NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X
Pickup, J. C., Mattock, M. B., Chusney, G. D., & Burt, D. J. (1997) · Diabetologia · doi:10.1007/s001250050822 · Cited by 1,246
Relation of C-Reactive Protein and Coronary Heart Disease in the MRFIT Nested Case-Control Study
Kuller, L. H., Tracy, R. P., Shaten, J., & Meilahn, E. N. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008963 · Cited by 1,098
Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes
Festa, A., D’Agostino, R., Tracy, R. P., & Haffner, S. M. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1131 · Cited by 1,057
Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,050
Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus
Haffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 881
C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study
Mendall, M. A., Patel, P., Ballam, L., Strachan, D. P., & Northfield, T. C. (1996) · BMJ · doi:10.1136/bmj.312.7038.1061 · Cited by 851
C-Reactive Protein as a Cardiovascular Risk Factor
Lagrand, W. K., Visser, C. A., Hermens, W. T., Niessen, H. W. M., Verheugt, F. W. A., Wolbink, G., & Hack, C. E. (1999) · Circulation · doi:10.1161/01.cir.100.1.96 · Cited by 833
Hypertension and the Pathogenesis of Atherosclerosis
Alexander, R. W. (1995) · Hypertension · doi:10.1161/01.hyp.25.2.155 · Cited by 785
Insulin Inhibits Intranuclear Nuclear Factor B and Stimulates I B in Mononuclear Cells in Obese Subjects: Evidence for an Anti-inflammatory Effect?
Dandona, P., Aljada, A., Mohanty, P., Ghanim, H., Hamouda, W., Assian, E., & Ahmad, S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7623 · Cited by 698
C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells
Devaraj, S., Xu, D. Y., & Jialal, I. (2003) · Circulation · doi:10.1161/01.cir.0000052617.91920.fd · Cited by 641
Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression and Migration in Human Vascular Smooth Muscle Cells
Marx, N., Schönbeck, U., Lazar, M. A., Libby, P., & Plutzky, J. (1998) · Circulation Research · doi:10.1161/01.res.83.11.1097 · Cited by 585
Relationship Between Insulin Resistance and an Endogenous Nitric Oxide Synthase Inhibitor
Stuehlinger, M. (2002) · JAMA · doi:10.1001/jama.287.11.1420 · Cited by 578
Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects
Tracy, R. P., Psaty, B. M., Macy, E., Bovill, E. G., Cushman, M., Cornell, E. S., & Kuller, L. H. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.10.2167 · Cited by 539
Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output.
Lang, C. H., Dobrescu, C., & Bagby, G. J. (1992) · Endocrinology · doi:10.1210/endo.130.1.1727716 · Cited by 535
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7157 · Cited by 520
Prospective Study of C-Reactive Protein in Relation to the Development of Diabetes and Metabolic Syndrome in the Mexico City Diabetes Study
Han, T. S., Sattar, N. A., Williams, K., González‐Villalpando, C., Lean, M. E. J., & Haffner, S. M. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2016 · Cited by 512
The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones
Arner, P. (2003) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(03)00024-9 · Cited by 423
Inflammatory Cytokines Impair Endothelium-Dependent Dilatation in Human Veins In Vivo
Bhagat, K., & Vallance, P. J. (1997) · Circulation · doi:10.1161/01.cir.96.9.3042 · Cited by 409
Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice
Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S. M., Wakino, S., Noh, G. J., Palinski, W., Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.3.365 · Cited by 389
PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer
Murphy, G. J., & Holder, J. C. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01559-5 · Cited by 386
A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes
Sutton, M. S. J., Rendell, M., Dandona, P., Dole, J., Murphy, K., Patwardhan, R., Patel, J., & Freed, M. I. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2058 · Cited by 254
Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease
Cleland, S. J., Sattar, N. A., Petrie, J. R., Forouhi, N. G., Elliott, H. L., & Connell, J. (2000) · Clinical Science · doi:10.1042/cs0980531 · Cited by 250
Induction of T-cell activation by oxidized low density lipoprotein.
Frostegård, J., Wu, R., Giscombe, R., Holm, G., Lefvert, A., & Nilsson, J. (1992) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.12.4.461 · Cited by 243
Rosiglitazone reduces urinary albumin excretion in type II diabetes
Bakris, G. L., Viberti, G. C., Weston, W. M., Heise, M. A., Porter, L. E., & Freed, M. I. (2003) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001444 · Cited by 240
Suppression of Nuclear Factor- B and Stimulation of Inhibitor B by Troglitazone: Evidence for an Anti-inflammatory Effect and a Potential Antiatherosclerotic Effect in the Obese
Ghanim, H., Garg, R., Aljada, A., Mohanty, P., Kumbkarni, Y., Assian, E., Hamouda, W., & Dandona, P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7309 · Cited by 229
Rosiglitazone Improves Insulin Sensitivity and Lowers Blood Pressure in Hypertensive Patients
Raji, A., Seely, E. W., Bekins, S. A., Williams, G. H., & Simonson, D. C. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.172 · Cited by 215
Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Chu, N. V., Kong, A. P. S., Kim, D. D. H., Armstrong, D. A., Baxi, S. C., Deutsch, R., Caulfield, M. P., Mudaliar, S. R. D., Reitz, R. E., Henry, R. R., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.542 · Cited by 194
Tumor Necrosis Factor Stimulates Hepatic Lipid Synthesis and Secretion*
FEINGOLD, K. R., Serio, M., Adi, S., MOSER, A. H., & Grünfeld, C. (1989) · Endocrinology · doi:10.1210/endo-124-5-2336 · Cited by 183
Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-alpha.
Youd, J. M., Rattigan, S., & Clark, M. G. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1904 · Cited by 180
Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells
Ganapathi, M. K., Rzewnicki, D., Samols, D. R., Jiang, S. L., & Kushner, I. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.4.1261 · Cited by 171
Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden
Brevetti, G., Silvestro, A., Giacomo, S. D., Bucur, R., Donato, A. D., Schiano, V., & Scopacasa, F. (2003) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(03)00124-1 · Cited by 165
A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus
Chilcott, J. B., Tappenden, P., Jones, M. L., & Wight, J. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80078-8 · Cited by 151
Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes
Wigmore, S. J., Fearon, K. C. H., Maingay, J. P., Lai, P. B. S., & Ross, J. A. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.4.e720 · Cited by 150
Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells
Stopeck, A., NICHOLSON, A. C., Mancini, F. P., & Hajjar, D. P. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85360-7 · Cited by 149
Nuclear Factor- B Suppressive and Inhibitor- B Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action?
Aljada, A., Garg, R., Ghanim, H., Mohanty, P., Hamouda, W., Assian, E., & Dandona, P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7564 · Cited by 146
Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients
Nakamura, T., Ushiyama, C., Shimada, N., Hayashi, K., Ebihara, I., & Koide, H. (2000) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(00)00124-0 · Cited by 145
Antiinflammatory and Antiarteriosclerotic Effects of Pioglitazone
Ishibashi, M., Egashira, K., Hiasa, K., Inoue, S., Ni, W., Zhao, Q. D., Usui, M., Kitamoto, S., Ichiki, T., & Takeshita, A. (2002) · Hypertension · doi:10.1161/01.hyp.0000036396.64769.c2 · Cited by 141
Troglitazone Reduces Reactive Oxygen Species Generation by Leukocytes and Lipid Peroxidation and Improves Flow-Mediated Vasodilatation in Obese Subjects
Garg, R., Kumbkarni, Y., Aljada, A., Mohanty, P., Ghanim, H., Hamouda, W., & Dandona, P. (2000) · Hypertension · doi:10.1161/01.hyp.36.3.430 · Cited by 139
Vascular Inflammation Is Negatively Autoregulated by Interaction Between CCAAT/Enhancer-Binding Protein-δ and Peroxisome Proliferator-Activated Receptor-γ
Takata, Y., Kitami, Y., Yang, Z., Nakamura, M., Okura, T., & Hiwada, K. (2002) · Circulation Research · doi:10.1161/01.res.0000031271.20771.4f · Cited by 128
Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled Study
Füllert, S., Schneider, F., Haak, E., Rau, H., Badenhoop, K. W. J., Lübben, G., Usadel, K.-H., & Konrad, T. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020963 · Cited by 122
Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?
N., C., & J., C. (2002) · Diabetologia · doi:10.1007/s00125-002-0975-6 · Cited by 116
Physiological Increments in Plasma Insulin Concentrations Have Selective and Different Effects on Synthesis of Hepatic Proteins in Normal Humans
Feo, P. D., Volpi, E., Lucidi, P., Cruciani, G., Reboldi, G., Siepi, D., Mannarino, E., Santeusanio, F., Brunetti, P., & Bolli, G. B. (1993) · Diabetes · doi:10.2337/diab.42.7.995 · Cited by 111
C-reactive protein increases production of IL-1α, IL-1β, and TNF-α, and expression of mRNA by human alveolar macrophages
Rochemonteix, B. G.-D., Wiktorowicz, K., Kushner, I., & Dayer, J. (1993) · Journal of Leukocyte Biology · doi:10.1002/jlb.53.4.439 · Cited by 109
Flow-mediated vasoactivity and circulating adhesion molecules in hypertriglyceridemia: Association with small, dense LDL cholesterol particles
Lupattelli, G., Lombardini, R., Schillaci, G., Ciuffetti, G., Marchesi, S., Siepi, D., & Mannarino, E. (2000) · American Heart Journal · doi:10.1067/mhj.2000.108508 · Cited by 108
Endothelial Dysfunction in Essential Hypertension
Panza, J. A. (1997) · Clinical Cardiology · doi:10.1002/j.1932-8737.1997.tb00009.x · Cited by 103
TNFα expression of subcutaneous adipose tissue in obese and morbid obese females: relationship to adipocyte LPL activity and leptin synthesis
Bulló, M., García‐Lorda, P., Peinado‐Onsurbe, J., Hernández, M., Castillo, D. D., Argilés, J. M. A., & Salas‐Salvadó, J. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801977 · Cited by 102
Nitric Oxide Synthase in Atherosclerosis and Vascular Injury
Channon, K. M., Qian, H., & George, S. E. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.8.1873 · Cited by 99
Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes
Ebeling, P. R., Teppo, A.-M., Koistinen, H. A., Viikari, J. S. A., R�nnemaa, T., Niss�n, M., Bergkulla, S., Salmela, P. I., Saltevo, J. T., & Koivisto, V. A. (1999) · Diabetologia · doi:10.1007/s001250051315 · Cited by 95
The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II Diabetic subjects
Yudkin, J. S., Panahloo, A., Stehouwer, C. D. A., EMEIS, J. J., Bulmer, K., Mohamed‐Ali, V., & Denver, A. E. (2000) · Diabetologia · doi:10.1007/s001250051500 · Cited by 88
Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets
Plutzky, J., Viberti, G. C., & Haffner, S. M. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00202-7 · Cited by 81
Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress
Shinozaki, K., Hirayama, A., Nishio, Y., Yoshida, Y., Ohtani, T., Okamura, T., Masada, M., Kikkawa, R., Kodama, K., & Kashiwagi, A. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01659-x · Cited by 78
Determinants of C-reactive protein concentration in blood.
de Maat, M. P., & Kluft, C. (2001) · PubMed · Cited by 66
Rapid automated enzyme immunoassay of serum amyloid A
Wilkins, J. A., Gallimore, J. R., Tennent, G. A., Hawkins, P. N., Limburg, P. C., van Rijswijk, M. H., Moore, E. G., & Pepys, M. B. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.7.1284 · Cited by 65
Nuclear Factor- B Suppressive and Inhibitor- B Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action?
Aljada, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3250 · Cited by 64
Plaque Disruption and Thrombosis
Shah, P. K. (2000) · Cardiology in Review · doi:10.1097/00045415-200008010-00007 · Cited by 61
Peroxisome proliferator-activated receptors in endothelial cell biology
Plutzky, J. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200110000-00006 · Cited by 58
Determinants of C-reactive protein concentration in blood
de Maat, M., & Kluft, C. (2001) · BMC News and views · doi:10.1186/2048-4623-1-s2-002 · Cited by 37
Modulation of vascular inflammation by PPARs
Tham, D. M., Wang, Y., & Rutledge, J. C. (2003) · Drug News & Perspectives · doi:10.1358/dnp.2003.16.2.740244 · Cited by 36
Modulation of Early Immune Responses and Suppression of Trypanosoma brucei brucei Infections by Surgical Denervation of the Spleen
Liu, Y., Mustafa, M., Li, H., Nuortio, L., Mustafa, A., & Bakhiet, M. (2000) · NeuroImmunoModulation · doi:10.1159/000026450 · Cited by 33
Insulin resistance affects endothelium-dependent acetylcholine-induced coronary artery response
Inoue, T. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1872 · Cited by 32
Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents
Dandona, P., & Aljada, A. (2004) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00259-3 · Cited by 28
Troglitazone Reduces the Expression of PPARγ While Stimulating That of PPARα in Mononuclear Cells in Obese Subjects1
Aljada, A., Ghanim, H., Friedman, J., Garg, R., Mohanty, P., & Dandona, P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7624 · Cited by 22
Variability in the measurement of intracoronary ultrasound images: implicatioNs for the identification of atherosclerotic plaque regression
Foster, G. P., Mittleman, M. A., Koch, M., Abela, G. S., & ZARICH, S. W. (1997) · Clinical Cardiology · doi:10.1002/clc.4960200105 · Cited by 21
Global public goods: international cooperation in the 21st century edited by Inge Kaul, Isabelle Grunberg and Marc Stern Oxford University Press, 1999, published for UNDP
Collins, P. (2001) · Public Administration and Development · doi:10.1002/pad.133 · Cited by 11
Troglitazone Reduces the Expression of PPAR While Stimulating That of PPAR in Mononuclear Cells in Obese Subjects
Aljada, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3130 · Cited by 8

Research works printed but not linked: 7

10.1210/jc.86.7.3257 · DOI
Okouchi M, 2001, Protective actions of pioglitazone and gliclazide on endothelial‐neutrophil adherence and endothelial surface expression of ICAM‐1 mediated by high concentrations of insulin, Diabetes, 50, A163
Lebovitz HE, 2001, diabetes, J Clin Endocrinol Metab, 86, 280
10.1210/jc.86.3.1306 · DOI
Mohanty P, 2001, Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein‐1 (MCP‐1): evidence of a potent anti‐inflammatory effect, Diabetes, 50, A68
Natali A, 2002, diabetic patients, Diabetes, 51, A142
Choi SH, 2003, diabetes, Diabetes, 52, A19

Sorted by citations

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
The metabolic syndrome
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
2007 Guidelines for the Management of Arterial Hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,870
2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
The metabolic syndrome
Eckel, R. H., Grundy, S. M., & Zimmet, P. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,755

See all 140

Authors: Nesto, R.
Affiliations: Lahey Hospital and Medical Center (US)
Corresponding author: Nesto, R.
Venue: Diabetic Medicine
Publisher: Wiley
Published: 2004-07-20
Volume: 21
Issue: 8
Pages: 810-817
ISSN: 0742-3071 (ISSN-L)
1464-5491
DOI: 10.1111/j.1464-5491.2004.01296.x
OpenAlex: W2050135792
Cited by: 140
References: 76
Citations by year: 2026: 4 · 2025: 8 · 2024: 1 · 2023: 5 · 2022: 6 · 2021: 1 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 1 · 2015: 3 · 2014: 4 · 2013: 6 · 2012: 5
FWCI: 12.22
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Diabetic Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords: C-reactive protein, inflammation, type 2 diabetes, cardiovascular disease, insulin resistance, thiazolidinediones, insulin sensitizers, endothelial dysfunction, metabolic syndrome, atherogenesis, plasminogen activator inhibitor-1, TNF-α, reactive oxygen species, dyslipidemia, hypertension, macrovascular complications
MeSH terms: Arteriosclerosis, C-Reactive Protein, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Inflammation, Insulin Resistance, Risk Factors, Metabolic Syndrome, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

C‐reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin‐sensitizing treatment with thiazolidinediones

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks